Post

Allecra’s Exblifep provides valuable new weapon to tackle ESBL-mediated AMR

The FDA has approved Allecra Therapeutics's novel antibiotic combination, Exblifep (cefepime/enmetazobactam), to treat complicated urinary tract infections (cUTIs), including acute …

AbbVie and Genmab’s Epkinly joins BiTE competition in follicular lymphoma 

On 27 February, AbbVie and Genmab’s Epkinly (epcoritamab) was granted Priority Review by the FDA for a supplemental biologics licence …

APAC led in trials for 2023, with the majority in Phase II

According to leading data and analytics company GlobalData’s Clinical Trials Database, among the clinical trials for 2023, Phase II led …

FDA lifts two-year clinical hold on CytoDyn’s HIV trial

The FDA has lifted the clinical hold on CytoDyn’s leronlimab, allowing the company to evaluate the therapy as a treatment …

Artiva prepares to kick off Phase I/II trial for NK cell therapy

Artiva Therapeutics is looking to dose the first patient in a Phase I/II trial assessing its cell therapy AlloNK in …